Literature DB >> 25541063

Cytotoxic and genotoxic effects of high concentrations of the immunosuppressive drugs cyclosporine and tacrolimus in MRC-5 cells.

H L Cilião1, D L Ribeiro2, R B O Camargo-Godoy3, A F L Specian2, J M Serpeloni4, I M S Cólus2.   

Abstract

Immunosuppressive drugs are used to suppress immune system activity in transplant patients and reduce the risk of organ rejection. The present study evaluated the potential cytotoxic, genotoxic and mutagenic of the immunosuppressive drugs cyclosporine (CsA) and tacrolimus (FK-506) on normal human fibroblasts (MRC-5 cells). Based on plasma concentrations of the immunosuppressive drugs, which were obtained from the records of kidney transplant patients at the Kidney Institute of Londrina, Brazil, 11 concentrations of each immunosuppressive were chosen to evaluate cell viability using the MTT assay. From these results, CsA and FK-506 concentrations of 135, 300, 675, and 1520 ng/ml and 8, 16, 24, and 32 ng/ml, respectively, were evaluated using (i) the comet assay, (ii) the nuclear division index (NDI), (iii) the micronucleus test (CBMN) and (iv) cell proliferation curves generated by quantifying cell numbers and protein levels. In this study, 1520 to 3420 ng/ml CsA decreased cell viability after 48 h of exposure. Genotoxic effects were observed only with a concentration of 1520 ng/ml after 3h of exposure and with concentrations of 675 and 1520 ng/ml after 24h of exposure. Mutagenic effects were observed only for the concentration of 1520 ng/ml. FK-506 decreased cell viability after 72 h of exposure for concentrations up to 20 ng/ml; genotoxic effects were observed with concentrations up to 8 ng/ml for both treatment times (3 and 24h) and mutagenic effects were observed with concentrations of 24 and 32 ng/ml after 24h of treatment. The cell proliferation curves demonstrated the absence of cytostatic effects of these drugs, and these data were confirmed by the NDI analysis. Our results suggest that concentrations lower than 300 ng/ml of CsA and 16 ng/ml of FK-506 are safe for use, as they did not induce genotoxic and mutagenic damage or affect MRC-5 cell viability and proliferation.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Comet assay; Immunosuppressive drugs; Kidney transplant; MRC-5 cells; MTT assay; Micronucleus test

Mesh:

Substances:

Year:  2014        PMID: 25541063     DOI: 10.1016/j.etp.2014.11.008

Source DB:  PubMed          Journal:  Exp Toxicol Pathol        ISSN: 0940-2993


  5 in total

1.  LDH, proliferation curves and cell cycle analysis are the most suitable assays to identify and characterize new phytotherapeutic compounds.

Authors:  Ana Flávia L Specian; Juliana M Serpeloni; Katiuska Tuttis; Diego L Ribeiro; Heloísa L Cilião; Eliana A Varanda; Miriam Sannomiya; Wilner Martinez-Lopez; Wagner Vilegas; Ilce M S Cólus
Journal:  Cytotechnology       Date:  2016-06-25       Impact factor: 2.058

2.  Synthesis and biological evaluation of the progenitor of a new class of cephalosporin analogues, with a particular focus on structure-based computational analysis.

Authors:  Anna Verdino; Giovanni Vigliotta; Deborah Giordano; Ivana Caputo; Annunziata Soriente; Margherita De Rosa; Anna Marabotti
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

3.  Potential Mechanism of Action of Cyclosporin A in Human Dermal Fibroblasts-Transcriptomic Analysis of CYPs.

Authors:  Grażyna Janikowska; Alina Pyka-Pająk; Tomasz Janikowski; Jolanta Adamska; Urszula Mazurek; Przemysław Jędrusik
Journal:  Molecules       Date:  2018-07-05       Impact factor: 4.411

4.  Harnessing Rift Valley fever virus NSs gene for cancer gene therapy.

Authors:  Alicia M Davis; Tristan A Scott; Kevin V Morris
Journal:  Cancer Gene Ther       Date:  2022-04-07       Impact factor: 5.854

5.  Poly Organotin Acetates against DNA with Possible Implementation on Human Breast Cancer.

Authors:  George K Latsis; Christina N Banti; Nikolaos Kourkoumelis; Constantina Papatriantafyllopoulou; Nikos Panagiotou; Anastasios Tasiopoulos; Alexios Douvalis; Angelos G Kalampounias; Thomas Bakas; Sotiris K Hadjikakou
Journal:  Int J Mol Sci       Date:  2018-07-14       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.